Completed PHASE2 INTERVENTIONAL 3-arm NCT00282178

Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo

A 36 Week Three-Center Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo

Sponsor: AstraZeneca

Conditions Hypertension Obesity

Interventions Candesartan Hydrochlorothiazide Placebo

Updated 7 times since 2017 Last updated: Oct 15, 2008 Started: Apr 30, 2005 Primary completion: Mar 31, 2006 Completion: Apr 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Hypertension and Obesity, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 7 data snapshots since 2005. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

7 versions recorded

Mar 2025 — Present [monthly]

Completed PHASE2
Feb 2025 — Mar 2025 [monthly]

Completed PHASE2
Sep 2024 — Feb 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Sahlgrenska University Hospital
Umeå University

Data source: Umeå University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Umeå, Sweden